News & Updates
Filter by Specialty:
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
Vonoprazan, a potassium competitive acid blocker (PCAB), is better than proton pump inhibitors (PPI) for the treatment of Helicobacter pylori and erosive oesophagitis, according to a new meta-analysis.
Potassium competitive acid blockers go toe-to-toe with PPI in gastric acid diseases
21 Oct 2022
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022
Sugar-sweetened drink intake tied to increased IBD risk
Consumption of sugar-sweetened beverages (SSBs) was associated with increased risk of inflammatory bowel disease (IBD), a large population-based study suggests. This association was not found with artificially sweetened beverages (ASBs) and natural juices.
Sugar-sweetened drink intake tied to increased IBD risk
18 Oct 2022
Anti-TNF continuation after pregnancy prevents relapse in women with IBD
Treatment continuation with antitumour necrosis factor (anti-TNF) after 24 weeks of pregnancy seems to provide benefits in terms of inflammatory bowel disease (IBD) activity and prematurity without affecting neonatal outcomes and serious infections in newborns, reports a study.
Anti-TNF continuation after pregnancy prevents relapse in women with IBD
16 Oct 2022
Sigmoidoscopy screening offers 15-year benefit in CRC incidence, mortality
Sigmoidoscopy screening provides a significant and sustained effect on colorectal cancer (CRC) incidence and mortality for 15 years, according to a pooled analysis of randomized trials.